ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 211

The Epidemiology of Gout: Marked Increase in Incidence and Comorbidities over 20 Years

Mohanad Elfishawi1, Nour Zleik1, Zoran Kvrgic1, Clement J. Michet Jr.2, Cynthia S. Crowson3, Eric L. Matteson4 and Tim Bongartz1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Comorbidity, Epidemiologic methods, gout and population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Several studies have suggested that the prevalence of gout has increased over recent years. The majority of this data has been derived from insurance claims databases. However, there are few data available regarding a possible change in the incidence of gout in the United States. We therefore aimed to determine whether there has been a change in the incidence of gout over the last 20 years, and evaluate possible changes in the clinical presentation of gout.

 

Methods: The individual medical records of all patients with a potential diagnosis of gout in a defined geographic cohort were reviewed using a resource insuring complete medical record capture. All individuals with a possible diagnosis of incident gout during the time periods January 1st 1989 – December 31st 1992 and January 1st 2009 – December 31st 2010 were identified.  Incident cases had to fulfill at least 1 of 3 criteria: the 1977 American College of Rheumatology proposed criteria for gout, the Rome or New York criteria.  Demographic and clinical data were abstracted for every incident case. Clinical characteristics were compared between time-periods using chi-square tests. Incidence rates with 95% confidence intervals (CI) were age- and sex-adjusted to the 2010 U.S. white population.

 

Results: A total of  158 patients with new-onset  gout were identified during the 4 year time period between 1989-1992 and 271 patients between the 2 year time period between 2009-2010, translating into age- and sex adjusted  incidence rates of 52.1/100 000 (95%CI 43.7-60.5) and 106.9/100 000 (95%CI 94.1-119.8), respectively. The incidence rate ratio for gout of 2.57 (95%CI; 2.11, 3.13) increased significantly over the last 20 years.

Patients diagnosed with gout between 2009-2010 were less likely to present with isolated podagra compared to patients diagnosed 20 years ago (67% versus 80%). Patients with gout incident in the recent period  2009-2010 had higher likelihood of having comorbid conditions compared with 1989-1992,  such as hypertension (73% vs. 54%), diabetes (27% vs. 6%), kidney disease (32% vs. 11%), hyperlipidemia (65% vs. 21%), and heart failure (15% vs. 6%), respectively, at the time of their first gout flare. The likelihood of obesity among patient with incident gout increased from 37% to 56% over the last 20 years – with an increase of morbid class III obesity from 3% to 13%.

Conclusion: The incidence of gout has more than doubled in our population-based cohort over the last 20 years. This observation appears to be consistent with the increase in prevalence reported in several studies to date. Patients have become more likely to present with atypical presentations in joint areas other than the 1st MTP joint, which may make the diagnosis more challenging.

The marked increase in various cardiovascular comorbidities and risk factors among patients with incident gout is concerning and emphasizes that gouty arthritis rarely occurs as a stand-alone problem, but rather must be seen as a manifestation of serious systemic metabolic disease.


Disclosure: M. Elfishawi, None; N. Zleik, None; Z. Kvrgic, None; C. J. Michet Jr., None; C. S. Crowson, None; E. L. Matteson, Novartis/Sanofi/Centocor-Jansen/Celgene/Amgen/Roche/Genentech/Mesoblast/Pfizer, 2; T. Bongartz, None.

To cite this abstract in AMA style:

Elfishawi M, Zleik N, Kvrgic Z, Michet CJ Jr., Crowson CS, Matteson EL, Bongartz T. The Epidemiology of Gout: Marked Increase in Incidence and Comorbidities over 20 Years [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-epidemiology-of-gout-marked-increase-in-incidence-and-comorbidities-over-20-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-epidemiology-of-gout-marked-increase-in-incidence-and-comorbidities-over-20-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology